In acute myeloid leukemia, FTO was shown to control stem cell differentiation through the ASB2/RARA axis, and FTO was revealed to affect immunotherapy by regulating intracellular factors (PD-1, CXCR4, and SOX10) in melanoma. This evidence concerns the gene RARA and acute myeloid leukemia.